First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open-Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer
https://www.powershow.com/view2b/402b84-NmNiY/First_Results_of_the_NeoALTTO_Trial_BIG_01-06_EGF_106903__A_Phase_III_Randomized_Open-Label_Neoadjuvant_Study_of_Lapatinib_Trastuzumab_and_Their_Combination_Plus_Paclitaxel_in_Women_with_HER2-Positive_Primary_Breast_Cancer_powerpoint_ppt_presentation
Icons create by Freepik from www.flaticon.com/